Axial Spondyloarthritis

ATLANTA — Certolizumab pegol and bimekizumab were associated with improvements ranging from work productivity to disease activity in patients with spondyloarthritic conditions, according to findings presented in three abstracts at ACR/ARP 2019.

ATLANTA — Ixekizumab combined with conventional background medication is superior to both conventional background medication alone and placebo in improving signs, symptoms and inflammation based on MRI among patients with nonradiographic axial spondyloarthritis, according to data presented at ACR/ARP 2019.

ATLANTA — A daily regimen of 15 mg upadacitinib was significantly more effective than placebo in improving signs, symptoms, function and imaging among patients with active ankylosing spondylitis, according to the presenter at ACR/ARP 2019.

Among patients with axial spondyloarthritis receiving their first TNF inhibitor, 27% achieve inactive disease, defined by the Ankylosing Spondylitis Disease Activity Score, after 6 months, with approximately 80% continuing treatment after 1 year, according to data published in Annals of the Rheumatic Diseases.

Alcohol consumption is significantly associated with spinal structural progression in patients with axial spondyloarthritis, according to data published in Arthritis Research & Therapy.

Consistent follow-up visits with the same physician and treatment with subcutaneous or IV drugs are associated with better patient-reported experiences among those with inflammatory arthritis, according to findings published in the Journal of Clinical Rheumatology.

Adults with active ankylosing spondylitis despite treatment with a first TNF-inhibitor, as well as those with stable disease receiving an originator TNF inhibitor, should not be switched to a biosimilar, according to updated recommendations from the American College of Rheumatology published in Arthritis Care & Research.